Q32 Bio Inc. (QTTB) News
Follow Q32 Bio Inc. (QTTB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Q32 Bio Reports Q3 2026 Net Loss of $8.9 Million
Q32 Bio reported a net loss of $8.9 million, or $0.26 per share, for the third quarter of 2026, versus a $7.4 million loss, or $0.60 per share, a year earlier. Cash and cash equivalents totaled $289.6 million at Septembe
EQUITY | Nov 04, 2026, 12:13 PM UTC
M
Q32 Bio Reports Third-Quarter 2026 Financial Results
EQUITY | Nov 04, 2026, 12:01 PM UTC
M
Q32 Bio Reports Third-Quarter 2026 Results and Clinical Update
Q32 Bio presented additional 36-week results and 16-week off-drug findings from Part B of its SIGNAL-AA trial of bempikibart at the EADV Congress 2026. The company said the data supports further development of bempikibar
EQUITY | Nov 04, 2026, 11:59 AM UTC
L
Q32 Bio Initiated at Buy by Jefferies
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 02:11 PM UTC
H
QTTB - Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
QTTB - Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
GEOPOLITICS | Sep 21, 2026, 01:16 PM UTC
L
QTTB: Phase II data show robust efficacy for bempikibart in alopecia areata, supporting phase III plans
The session highlighted strong phase II results for bempikibart in alopecia areata, with robust efficacy and durable responses, and outlined a clear path to phase III with sufficient funding. The market opportunity is su
NEWS | Sep 15, 2026, 04:53 PM UTC
L
QTTB: Promising phase II results for an IL-7/TSLP biologic in AA set the stage for pivotal trials
The session highlighted a promising IL-7/TSLP-targeting biologic for alopecia areata, with strong phase II results and a large addressable market. Phase III will leverage lessons from earlier trials, with robust enrollme
NEWS | Sep 15, 2026, 04:25 PM UTC
L
QTTB: Bempikibart shows promising efficacy and safety in alopecia areata, with phase III set for next year
Lead asset bempikibart demonstrated strong efficacy and a favorable safety profile in alopecia areata, with a large U.S. market opportunity and plans for a single pivotal phase III trial. Additional indications and dosin
EQUITY | Sep 09, 2026, 09:19 PM UTC
L
QTTB: Bempikibart demonstrates strong efficacy and safety in alopecia areata, with phase III set for next year
Recent 36-week data in alopecia areata show bempikibart matches JAK efficacy with a better safety profile, targeting a growing multibillion-dollar US market. Phase III is planned for next year, with additional indication
FX | Sep 09, 2026, 08:54 PM UTC
M
QTTB backs Phase II bempikibart results for Phase III move
Positive Phase II data for bempikibart in alopecia areata, with JAK-like efficacy and a strong safety profile, support plans to advance to Phase III and explore additional indications.
EQUITY | Sep 08, 2026, 09:05 PM UTC
L
QTTB - Q32 Bio to Participate in Upcoming September Investor Conferences
QTTB - Q32 Bio to Participate in Upcoming September Investor Conferences
EQUITY | Sep 01, 2026, 10:59 AM UTC
L
Q32 Bio to participate in upcoming September investor conferences
Q32 Bio Inc. said management will participate in upcoming September investor conferences. The company is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases.
EQUITY | Sep 01, 2026, 10:59 AM UTC
M
Morgan Stanley starts QTTB at Overweight, $34 target
Morgan Stanley initiates coverage of QTTB with an Overweight rating and a $34 price target.
EQUITY | Aug 24, 2026, 12:10 PM UTC
L
Morgan Stanley initiates QTTB at Overweight, $34.00 target
Morgan Stanley initiates QTTB at Overweight with a $34.00 price target.
EQUITY | Aug 24, 2026, 11:59 AM UTC
L
Morgan Stanley initiates QTTB at Overweight, sets $34 target
Morgan Stanley initiates QTTB with an Overweight rating and a $34 price target.
EQUITY | Aug 24, 2026, 10:25 AM UTC
L
QTTB - Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
QTTB - Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 05, 2026, 10:59 AM UTC
H
Stock Market Today: Dow Futures Gain, S&P 500 Slips as US and Iran Exchange Strikes—Saratoga, Exxon Mobil, Levi Strauss in Focus
U.S. stock futures were mixed on Monday, as the Dow Jones index advanced, while the Nasdaq 100 and S&P 500 indices fell, following Friday’s higher close. Late Sunday, global markets turned cautious after the U.S. launche
CENTRAL_BANK | Jul 13, 2026, 10:00 AM UTC
L
QTTB Files Mixed Shelf
QTTB files Form S-3 for $300,000,000 mixed shelf
EQUITY | Jun 25, 2026, 08:13 PM UTC